VanEck Biotech ETF (NASDAQ:BBH) Sees Large Volume Increase – Should You Buy?

VanEck Biotech ETF (NASDAQ:BBH) saw an uptick in trading volume on Thursday. Approximately 4,806 shares traded hands during mid-day trading, a decline of 34% from the previous session’s volume of 7,289 shares. The stock last traded at $251.1030 and had previously closed at $250.46.

VanEck Biotech ETF Stock Down 1.4%

The business has a 50 day moving average price of $237.94 and a 200-day moving average price of $210.07.

Institutional Investors Weigh In On VanEck Biotech ETF

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of VanEck Biotech ETF during the third quarter valued at $74,000. Robertson Stephens Wealth Management LLC acquired a new stake in shares of VanEck Biotech ETF in the third quarter worth $276,000. Cyndeo Wealth Partners LLC bought a new position in VanEck Biotech ETF in the 3rd quarter worth approximately $318,000. Focus Financial Network Inc. bought a new stake in shares of VanEck Biotech ETF in the third quarter valued at about $240,000. Finally, BigSur Wealth Management LLC bought a new position in VanEck Biotech ETF in the third quarter worth $126,000. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.